Phase 1
N=100
Bunionectomy Study (0000-063)
Acute Pain
Bottom Line
View on ClinicalTrials.gov: NCT00601458 ↗Enrolled (actual)
100
Serious AEs
0.0%
Results posted
Apr 2010
Primary outcome: Primary: Total Patient Controlled Analgesic (PCA) Hydromorphone Consumption Over the 24 Hours Post-surgery — 2.94; 2.07; 5.96 milligrams — p=0.005
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 1
- Interventions
- pregabalin (Drug); naproxen sodium (Drug); Comparator: Placebo (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Merck Sharp & Dohme LLC
- Primary completion
- Jan 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Total Patient Controlled Analgesic (PCA) Hydromorphone Consumption Over the 24 Hours Post-surgery |
2.94; 2.07; 5.96 | 0.005 sig |
| SECONDARY Time to First Request of PCA Hydromorphone |
7.3; 9.1; 5.8 | 0.004 sig |
Summary
We are interested in whether bunionectomy can be used as a model to study the treatment of acute pain. It has been used to study the effect of Non-Steroidal Anti-inflammatory (NSAIDS) medications (such as ibuprofen) and other pain relieving drugs. We are interested to know if this model is useful to study other drugs for the treatment of acute pain. The other drugs being tested in this study are pregabalin and naproxen sodium. These drugs are approved for use by the Food and Drug Administration (FDA). This study is designed to test whether these two drugs are effective in treating pain after a bunionectomy.
Eligibility Criteria
Inclusion Criteria
- Patient is a man or woman between 18 and 65 years of age
- For Women of Child-bearing potential: woman who is currently not pregnant not nursing and who is willing to use a medically acceptable method of birth control from the time after the screening visit until completion of the follow-up visit
- Patient is scheduled to have a bunionectomy
- Patient must be willing to stay at the study site throughout the 48-hour observation period following surgery and is willing to complete a 2-week follow up
- Patient is capable of operating a Patient Controlled Analgesia device
Exclusion Criteria
- Patient is being treated for a disease and has not been on a stable dose of medication for at least 2 weeks prior to surgery
- Patient has used or intends to use any of the medications that are prohibited by the protocol, which could interfere with the evaluation of the study drugs
- Patient has an estimated creatinine clearance of < or = 60 mL per min
- Patient has a history of drug abuse or dependence, or patient has a positive urine drug screen
- Patient has a condition that prevents clear communication concerning pain perception (such as diabetic neuropathy, peripheral neuropathy, etc.)
Data sourced from ClinicalTrials.gov (NCT00601458). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.